TITLE

Biogen Idec and Elan Move Up Antegren Filing

PUB. DATE
February 2004
SOURCE
Chemical Market Reporter;2/23/2004, Vol. 265 Issue 8, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that biotechnology firms Biogen Idec and Elan Corp. expect to reduce a year off the anticipated development time for the multiple sclerosis treatment Antegren.
ACCESSION #
12349949

 

Related Articles

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Feb2011, Vol. 10 Issue 2, p4 

    The article provides updates on the development of drugs for multiple sclerosis. A complete response letter from the U.S. Food and Drug Administration (FDA) has been received by Teva Pharmaceutical Industries Ltd. for its supplemental New Drug Application (sNDA). Applications to update Tysabri...

  • Tysabri makers mulling risks, benefits. McGuire, Stephen // Medical Marketing & Media;May2005, Vol. 40 Issue 5, p10 

    Reports that Biogen Idec Inc. and Elan Corp. PLC do not expect to issue a decision on the fate of their jointly marketed multiple sclerosis drug, Tysabri, until the second half of 2005. Results of clinical trials; Biogen and Elan's reasons for voluntarily withdrawing Tysabri from the market in...

  • Biogen Idec, Elan Release Antegren Results for Approval.  // Chemical Market Reporter;11/15/2004, Vol. 266 Issue 17, p14 

    Reports on the release of the results of a late-stage trial of Antegren or natalizumab, a multiple sclerosis treatment developed by Biogen IDEC and Elan Corp. PLC in November 2004. Preparation for the U.S. Food and Drug Administration's final review of the drug; Composition of the drug; Safety...

  • Elan climbs on multiple sclerosis drug success.  // PharmaWatch: CNS;December2004, Vol. 3 Issue 12, p5 

    Reports that shares in Elan Corp. have climbed more than 10% following the announcement that its multiple sclerosis drug Antegren, developed in cooperation with Biogen Idec, performed well in phase III trials. Significant reduction of clinical relapse rates; One-year data from AFFIRM, an...

  • MS Drug Gets Priority Review.  // Chemical Market Reporter;7/5/2004, Vol. 266 Issue 1, p12 

    Reports on the move of the U.S. Food and Drug Administration to assign a priority review status to the biologics license application from Biogen Idec Inc. and Elan Corp. PLC. Use of the drug in treating multiple sclerosis; Submission of the application by the companies to the administration;...

  • Biogen and Elan to apply for EU approval of multiple sclerosis drug.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p8 

    Reports on the plan of Biogen Idec Inc. and Elan Corp. to submit an application for approval of their multiple sclerosis drug Antergen in Europe. Expectation of the pharmaceutical companies for the granting of the drug approval by the U.S. Food and Drug Administration; Success gained by the...

  • EMEA Finds More Tysabri PMLs.  // Bioworld Week;11/2/2009, Vol. 17 Issue 44, p2 

    The article reports on the decrease in shares of Biogen Idec Inc. and partner Elan Corp. PLC by 3.42 U.S. dollars, or 7 percent, to close at 43.81 dollars on October 23, 2009. Their shares have declined after the number of progressive multifocal leukoencephalopathy (PML) cases linked to multiple...

  • ROYALTY PHARMA LLC.  // MondayMorning;4/15/2013, Vol. 21 Issue 14, p1 

    The article offers information on the easing of its 6.6 billion U.S. dollars offer for pharmaceutical company Elan Corp. PLC by the company Royalty Pharma LLC. It mentions that Royalty Pharma LLC will pay more to the shareholders of Elan Corp. PLC if multiple sclerosis drug Tysabri achieves...

  • Biogen Idec climbs on multiple sclerosis drug success.  // PharmaWatch: Biotechnology;December2004, Vol. 3 Issue 12, p10 

    Reports that shares in Elan Corporation have risen following the announcement that its multiple sclerosis drug Antegren, developed in cooperation with Biogen Idec Inc., performed well in phase III trials. Reduction of clinical relapse rates; International study of patients with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics